5 minute read
Oct. 29, 2022
Neflamapimod: an Oral, Brain-Penetrant p38α Kinase Inhibitor
neflamapimod
oral p38α kinase inhibitor Ph. II candidate in neurology from SBDD and opt. Nat. Commun., Sep 21, 2022 EIP Pharma Inc, Boston, MA / Vertex, Cambridge, MA
Loading...
